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Abstract
Background
Muscle mass and function are perturbed by immobilization and remobilization. When mus-
cle mass changes, the quality and quantity of the extracellular matrix protein, particularly
the collagens, change with it. In this study, we investigated the temporal profile of three pep-
tide biomarkers derived from turnover of collagen type III and type VI in a long-term immobi-
lization and remobilization study. We also compared individual biomarker levels with Lean
body Mass (LBM) and changes therein, hypothesizing that these biomarkers would be bio-
markers of the remodeling processes associated with immobilization and/or remobilization.
Methods
In the Berlin bed rest study, 20 young men were recruited and randomly assigned to 8-
week’s strict bed rest with or without resistive vibration exercise countermeasure. We mea-
sured three neo-epitope ELISA kits in the serum samples of this study: Pro-C3, measured
the synthesis of collagen type III; Pro-C6, measured the synthesis of collagen type VI; and
C6Mmeasured the degradation of collagen type VI induced by MMP-2 and MMP-9
cleavage.
Results
Pro-C3 and Pro-C6 biomarkers are up-regulated with both immobilization and remobiliza-
tion, whereas C6M is hardly affected at all. We found that Pro-C3 and C6M levels are
related to LBM at baseline and that high levels of Pro-C6 are associated with smaller
changes in muscle mass during both immobilization and remobilization.
Conclusion
The Pro-C3 and–C6 biomarkers change likely reflect remodeling changes in response to
unloading or reloading, whereas C6M does not appear to respond to unloading. Pro-C3 and
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C6M levels correlate with LBM at baseline, while Pro-C6 is related to the anabolic and cata-
bolic responses to unloading and reloading.
Introduction/Background
Muscle mass and function are reduced with age, along with a range of pathologies and inactiv-
ity. It is reported that elderly men lose 1% leg lean mass per year [1], that 2–3% of muscle mass
is lost per week during immobilization [2] and sometimes even quicker with cachexia [3].
Impaired muscle mass and function in elderly or hospitalized individuals has been shown to be
associated with (co)morbidity and mortality [4]. With the population age increasing in the
industrialized world, maintaining functional independence shows increasing importance.
Nowadays, the diagnosis and monitoring of muscle loss rely on the imaging examination, e.g.
magnetic resonance imaging (MRI), computed tomography (CT) and dual-energy X-ray
absorptiometry (DXA) [4]. However, such examinations are not in widespread clinical use,
probably owing to its expensive cost and inconvenience to be used in routine clinical care. Uri-
nary and serological biomarkers such as creatinine and 3-methyl histidine have also been
shown to be able to assess muscle mass and could thus assist the management of muscle loss.
However, high variation and poor validity of these assays limit their use [5]. In summary, there
is an urgent need for biomarkers which can be used in the diagnosing and predicting muscle
function as well as monitoring anticatabolic and anabolic treatment outcomes [6].
Loss of muscle mass is driven by unbalanced turnover of muscle extracellular proteins [7,
8]. As protein turnover, particularly of extracellular proteins, can allow proteolytic fragments
to escape into the circulation, quantitative or qualitative changes in protein metabolism can
give rise to biomarker profiles that can be of use in monitoring muscle mass or function [5].
Collagens are important extracellular proteins of skeletal muscle, which could contribute to
the passive tension of muscle [9]. Collagen type III is expressed in most of the collagen type I
containing tissues except for bone, and is an important component of connective tissues, mus-
cle tissues and skin [10]. PIIINP is the N-terminal propeptide of collagen type III, which is
removed during mature collagen type III synthesis [11]. It has been reported to be related to
the anabolic response of hormone treatment [12, 13]. Recently, a new ELISA kit was developed
by applying monoclonal antibody targeting the N-protease cleavage site of collagen type III
propeptide, which could assess the true synthesis of collagen type III [14].
Collagen type VI is a unique extracellular collagen, which can form an independent microfi-
brillar network in the basement membrane of cells. It can interact with other matrix proteins
including collagens, biglycan, proteoglycans, etc [15–17]. In muscle, collagen type VI is part of
the sarcolemma and involved in anchoring the muscle fiber into the intramuscular extracellular
matrix, thus involved in force transmission [18, 19]. Moreover, mutations in collagen type VI
can cause Bethlem myopathy and Ullrich congenital muscular dystrophy [20]. It has been
reported that the C-terminus of collagen type VI α3 chain is cleaved off from the mature type
VI microfibril after secretion [21, 22]. Therefore, the level of C-terminus of α3 chain could
reflect the level of newly formed mature collagen type VI. In order to investigate the synthesis
of collagen type VI, we developed a Pro-C6 ELISA kit targeting the C-terminus of α3 chain. In
addition, collagen type VI is also a substrate of MMPs [23]. Previous studies showed that both
MMP-2 and MMP-9 are relevant to muscle atrophy [24, 25]. Therefore, collagen type VI deg-
radation fragment by MMP-2 and MMP-9 could be interesting in relation to immobilization
induced muscle atrophy.
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In this study, we measured three neo-epitope biomarkers Pro-C6 (measuring the C-termi-
nus α3(VI) chain) and C6M (measuring collagen type VI fragment degraded by MMP-2 and
MMP-9) [23], and Pro-C3 (measuring the synthesis of collagen type III) [14], which directly
measure the turnover of collagen type III and VI in the Berlin bed rest study–using bed rest
immobilization and remobilization as a human model of muscle atrophy and hypertrophy.
Materials and Methods
Bed rest study
The Berlin bed rest study (BBR) has been described elsewhere [26, 27]. Briefly, 20 healthy
young men were recruited and underwent a strict 8-week bed rest study. The 20 young men
were then randomly divided into two groups. The resistive vibration exercise group (RVE)
group was assigned to resistive vibration exercise 11 times per week. The resistive vibration
exercises were performed with a vibration exercise apparatus at the end of the beds, and with
the subject pulling themselves towards the vibration plate through waist and shoulder straps
and handles. The control group (CTRL) was not allowed to perform any exercise during the
8-week bed rest. The serum samples were obtained 2 days before the study (baseline), in the
bed rest period (BR) and in the following recovery period (R). The serum samples were stored
at -80°C until further measurement. The muscle mass of both groups were assessed by MRI
and DXA during the three periods. The study was approved by the ethics committee of the
Charité Universitätsmedizin Berlin. Subjects gave their written informed consent.
Antibody development for Pro-C6
We used the last 10 amino acids of the collagen type VI α3 chain (3168’KPGVISVMGT’3177,
Chinese Peptide Company, China) as the immunogenic peptide to generate specific monoclo-
nal antibodies. All the work on mice was approved by Beijing laboratory animal administration
office and animal ethics committee of Nordic Bioscience (Beijing). The methods used for
monoclonal antibody development were as previously described [28]. Briefly, 4-6-week-old
Balb/C mice were immunized subcutaneously with 200μl emulsified antigen with 60μg of the
immunogenic peptide. Consecutive immunizations were performed at 2-week intervals in
Freund's incomplete adjuvant, until stable sera titer levels were reached, and the mice were
bled from the 2nd immunization on. At each bleeding, the serum titer was detected and the
mouse with highest antiserum titer and the best native reactivity was selected for fusion. The
selected mouse was rested for 1 month followed by intraperitoneal boosting with 50μg of
immunogenic peptide in 100μl 0.9% sodium chloride solution 3 days before isolation of the
spleen for cell fusion.
The fusion procedure has been described elsewhere [29]. Briefly, mouse spleen cells were
fused with SP2/0 myeloma fusion partner cells. The fusion cells were raised in 96-well plates
and incubated in the CO2-incubator. Here standard limited dilution was used to promote
monoclonal growth. Cell lines specific to the selection peptide and without cross-reactivity to
neither elongated peptide (KPGVISVMGTA, Chinese Peptide Company, China) nor truncated
peptide (KPGVISVMG, American Peptide Company, USA) were selected and sub-cloned. At
last the antibodies were purified using an IgG column.
Pro-C6 assay protocol
ELISA-plates used for the assay development were Streptavidin-coated from Roche (cat.:
11940279). All ELISA plates were analyzed with the ELISA reader from Molecular Devices,
SpectraMax M, (CA, USA). We labeled the selected monoclonal antibody with horseradish
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peroxidase (HRP) using the Lightning link HRP labeling kit according to the instructions of
the manufacturer (Innovabioscience, Babraham, Cambridge, UK). A 96-well streptavidin plate
was coated with biotinylated synthetic peptide biotin-KPGVISVMGT (Chinese Peptide Com-
pany, China) dissolved in coating buffer (40 mM Na2HPO4, 7 mM KH2PO4, 137 mMNaCl,
2.7 mM KCl, 0.1% Tween 20, 1% BSA, pH 7.4) and incubated 30 minutes at 20°C. 20 μL of
standard peptide or samples diluted in incubation buffer (40 mMNa2HPO4, 7 mM KH2PO4,
137 mMNaCl, 2.7 mM KCl, 0.1% Tween 20, 1% BSA, 5% Liquid II, pH 7.4) were added to
appropriate wells, followed by 100 μL of HRP conjugated monoclonal antibody 10A3, and
incubated 21 hour at 4°C. Finally, 100 μL tetramethylbenzinidine (TMB) (Kem-En-Tec
cat.438OH) was added and the plate was incubated 15 minutes at 20°C in the dark. All the
above incubation steps included shaking at 300 rpm. After each incubation step the plate was
washed five times in washing buffer (20 mM Tris, 50 mM NaCl). The TMB reaction was
stopped by adding 100 μL of stopping solution (1% H2SO4) and measured at 450 nm with 650
nm as the reference.
Pro-C6 technical evaluation
The lower limit of detection (LLOD) was determined from 21 zero samples (i.e. buffer) and cal-
culated as the mean + 3x standard deviation. Upper limit of detection (ULOD) was determined
as the mean– 3xSD of 10 measurements of Standard A. The intra-assay and inter-assay varia-
tion was the mean variations of 8 QC samples run 12 independent times in duplicate. Dilution
recovery was determined in 4 serum samples and 4 heparin plasma samples and was calculated
as a percentage of recovery of diluted samples from the 100% sample. Correlation between
serum and plasma was determined in serum and the matched heparin plasma, citrate plasma,
EDTA plasma from 16 individuals (Innovative Research).
Measurement of Pro-C3, C6M assays in Berlin bed rest study
The protocols of Pro-C3, C6M assays have been described elsewhere [14, 23]. Briefly, in Pro-
C3 assay, a 96-well streptavidin plate was coated with biotinylated synthetic peptide and incu-
bated 30 minutes at 20°C. 20 μL of standard peptide or 1:2 diluted serum samples were added
to appropriate wells, followed by 100 μL of HRP conjugated monoclonal antibody NB61N-62,
and incubated 20 hour at 4°C. Finally, 100 μL TMB was added and the plate was incubated 15
minutes at 20°C in the dark. The TMB reaction was stopped by adding 100 μL of stopping solu-
tion (1% H2SO4) and measured at 450 nm with 650 nm as the reference. In C6M assay, biotiny-
lated synthetic peptide is coated to a 96-well streptavidin plate. 20 μL of standard peptide or 1:2
diluted serum samples are added, followed by 100 μL of HRP conjugated monoclonal antibody,
and incubated 1 hour at 20°C. The plate was read after the development by TMB.
Statistics
The biomarker data measured in the Berlin Bed Rest clinical study were initially subjected to a
distribution analysis in order to determine of transformation was necessary to obtain prerequi-
site normality. Then the data were subjected to mixed models repeated measures ANOVA
analysis, testing for Time and Treatment (CTRL vs. RVE) effects as well as TimeTreatment
interactions. This was done in the first instance for the entire Time Course, and then for the
time points covering the remobilization only (starting with the last immobilization time point).
If main effects were present, appropriate post hoc tests were performed, subjected to Bonfer-
roni correction for multiple testing. The correlation analyses between biomarkers and LBM
were performed with Graphpad Prism as a linear regression, yielding (parametric) Pearson
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correlation coefficients. Significance threshold is determined to be p<0.05 and data are pre-
sented as means ± SEMs where appropriate.
Results
Characterization of Pro-C6 assay
The chosen antibody 10A3 specifically recognized the last 10 amino acids of C-terminus
COL6A3 3168’KPGVISVMGT’3177, but did not recognize elongated peptide KPGVISVMGTA
or truncated peptide KPGVISVMG (Fig 1). Native reactivity of the chosen antibody was
assessed using human serum pool and human amniotic fluid pool. In the competitive ELISA,
the signals were partly inhibited by both serum and amniotic fluid (Fig 2A). Western blot
showed that the antibody recognized a band around 10kD, a signal which was completely
blocked in the presence of the standard peptide (Fig 2B).
The measurement range of the Pro-C6 competitive ELISA was determined providing a
range from 0.15ng/ml (LLOD) to 58.39ng/ml (ULOD). The inter- and intra- assay variability
are 15.2% and 4.8%, respectively. The dilution recovery in human serum and heparin plasma
were both within 100±20% (Table 1). The correlations between values in human serum and
three kinds of plasmas were relatively high (Fig 3, P<0.0001), showing that Pro-C6 levels are
independent of blood preparation method.
Pro-C6 biomarker profile in Berlin Bed Rest study
The Pro-C6 biomarker (Fig 4A) changed over time during the course of immobilization (sig-
nificant time effect, p<0.0001) in the form of an increase after approximately one week of
immobilization, reaching a peak level approximately 40% higher than baseline during the last
couple of weeks of immobilization (being significantly higher than baseline from BR19 to R28,
peaking at BR47, p = 0.0002). There were no differences between the RVE and CTRL group
Fig 1. Peptide specificity test of monoclonal antibody 10A3. The antibody only recognized the selection peptide, and has no cross reaction to neither
elongated peptide nor truncated peptide.
doi:10.1371/journal.pone.0144525.g001
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during the immobilization period (no significant treatment effects or treatmenttime
interactions).
During re-mobilization, both time and timetreatment interaction effects manifested them-
selves. This was in the form of an increase that peaked one week into remobilization (a 20%
increase relative to the last day of immobilization, BR56, p = 0.011), followed by a gradual
return to baseline values. The interaction effect was not manifested in any post hoc tests, owing
to high variation at the R7 time point.
When we compared individual biomarker levels of Pro-C6 with LBM and changes therein
(Table 2), we found that the level of Pro-C6 at baseline was not related to LBM at all, but the
level at BR47 was positively related to change in LBM during immobilization (R2 = 0.2794,
R = 0.529, p = 0.0166) meaning that higher levels of Pro-C6 were associated with lower loss of
LBM. We also found that Pro-C6 at R3 was negatively related to the amount of LBM (re)gained
during remobilization (R2 = 0.3365, R = 0.580, p = 0.0073), meaning that higher levels were
associated with less (re)gain of LBM during remobilization.
Fig 2. Pro-C6 reacted with human serum and amniotic fluid. (A) The signals in competitive ELISA were partly inhibited by human serum and human
amniotic fluid. (B) Western blot showed the specific bands in human serum (lane 1, 2) and amniotic fluid (lane 3, 4). The bands can be blocked in the
presence of selection peptide (lane 6–9).
doi:10.1371/journal.pone.0144525.g002
Table 1. Dilution recovery of Pro-C6 assay.
Serum samples Dilution recovery Heparin plasma samples Dilution recovery
undiluted 100 undiluted 100
dilution 1:2 91 dilution 1:2 105
dilution 1:4 91 dilution 1:4 100
dilution 1:8 80 dilution 1:8 109
Notes: Samples were diluted in serial 2-fold dilution steps concentration was measured in these serial dilutions. Dilution recovery was obtained by
multiplying measured concentrations with the dilution factor and expressed as percent of the concentration of the undiluted (starting) sample. The table
shows that the signal dilutes linearly and stays within +/- 20% within and 8-fold dilution range.
doi:10.1371/journal.pone.0144525.t001
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C6M biomarker profile in Berlin Bed Rest study
The C6M biomarker (Fig 4B) was essentially unchanged during the immobilization phase (no
time effect in the immobilization time period), but increased briefly 30–40% at the beginning
of remobilization (a significant time effect at p<0.0001 during the immobilization period).
There were no effect of RVE treatment during immobilization and although it may appear as if
the increase in the C6M signal is bigger in the CTRL group than in the RVE group, this did not
reach significance (the timetreatment interaction did not reach significance and thus no post
hoc test was made).
When we compared individual biomarker levels of C6M with LBM and changes therein
(Table 2), we found that the level of C6M at baseline correlated with the baseline LBM (R2 =
0.3540, R = 0.595, p = 0.0057), but not related to muscle loss during immobilization at BR47
nor to the amount of muscle (re)gained during remobilization at R3.
Pro-C3 biomarker profile in Berlin Bed Rest study
Pro-C3 (Fig 4C) displayed a significant time effect in the form of an initial decrease of approxi-
mately 20% upon immobilization (being significantly different from baseline from BR3
through BR12, p<0.004 for all time points) followed by an increase at the end of the immobili-
zation (BR40 being significantly different from baseline, p = 0.05). Interestingly, at the onset of
remobilization, a similar pattern could be observed with an initial decrease followed by an
increase (with time points R3 through R28 being significantly higher than baseline, p<0.03 for
all time points, and R3 being significantly higher than the last time point of immobilization,
BR56, p = 0.02). At the last two time points, 13 weeks following the onset of immobilization,
the biomarker levels were back to baseline. There were no significant between-group differ-
ences, nor a significant timetreatment interaction effect.
When we compared individual biomarker levels of Pro-C3 with LBM and changes therein
(Table 2), we found that individual levels of Pro-C3 correlated significantly with LBM at base-
line (R2 = 0.2869, R = 0.536, p = 0.0149). Furthermore, we found that the level of biomarker at
Fig 3. Correlation of Pro-C6 levels in three kinds of plasma and serum (matched samples, from 16 individuals). Linear regression analysis was
performed, plasma vs serum. The figure shows the strong correlations of Pro-C6 levels in serum and the three kinds of plasma (P<0.0001).
doi:10.1371/journal.pone.0144525.g003
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Fig 4. Biomarker changes relative to baseline (A, B, C) in the BBR1 study. (A) Pro-C6 changes relative
to baseline (%). (B) C6M changes relative to baseline (%). (C) Pro-C3 changes relative to baseline (%). “BR”
time points denote bed rest immobilization time points and “R” time points denote remobilization time points.
The number suffix denotes the number of days into the bed rest or remobilization period. “*” denotes the days
that have significantly different levels when compared to baseline, p<0.05. “#” denotes significant difference
in the level when compared to the last time point of the immobilization period (BR56), p<0.05. Data are
expressed as means ±SEMs.
doi:10.1371/journal.pone.0144525.g004
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its peak at BR47, correlated significantly with the amount of LBM lost during immobilization
(R2 = 0.2056, R = 0.453, p = 0.0447).
Discussion
Immobilization leads to loss of the lean body mass, predominantly in the form of skeletal mus-
cle, as was also the case for the present study (study previously described in detail, including
detailed changes in body composition) [27, 30]. Stable isotope studies have shown that atrophy
in most tissues and muscle in particular is driven by global decreases of synthesis to a larger
extent than increases in degradation [31, 32].
There is little research on the effect of immobilization on muscle ECM turnover on prote-
ome scale as well as for individual proteins. Naturally, turnover of individual proteins can be
regulated in a different manner. Looking at rodent studies, the total muscular collagen was
increased during immobilization [33]. Of particular interest, in the Miller study, immobiliza-
tion resulted in increases in collagen III protein [33], which occurs in despite of down-regu-
lated collagen III mRNA reported elsewhere in rat muscle unloading in a similar model [34].
In this paper, we report the modulation of serological collagen peptide biomarkers in
response to long-term unloading in the form of bed rest and subsequent reloading in the Berlin
Bed Rest study. In this study, the subjects were immobilized through bed rest with or without a
vibration device countermeasure for 8 weeks followed by remobilization through habitual
physical activity. Both groups lost muscle mass and strength during the immobilization, with
slightly more lost in the CTRL group than in the RVE group. Both group regained muscle mass
and strength during remobilization.
During immobilization, the biomarkers Pro-C3 and Pro-C6 display somewhat similar tem-
poral patterns. While Pro-C3 initially drops slightly following the onset of immobilization,
both Pro-C3 and Pro-C6 eventually increase with immobilization over time, 20% and 40%
respectively. At the onset of remobilization, a slight initial drop can again be observed followed
by an increase that on the part of Pro-C6 was bigger in the CTRL than in the RVE group, fol-
lowed by a return to baseline in both biomarkers. The C6M biomarker is essentially unrespon-
sive to bed rest unloading, but spikes briefly in response to reloading, with no significant
difference between groups.
Collagen type III is expressed ubiquitously in tensile stress bearing tissues, including, but
not restricted to, tendon, muscle, vasculature and skin. This essentially restricts expression to
Lean Body Mass. We have in two previous studies shown that baseline levels of the Pro-C3 bio-
marker correlate with LBM in healthy adults [14, 35]. We believe that the measured levels of
Table 2. Correlationmatrix for biomarker vs. anthropometric variables.
Pro-C6 C6M Pro-C3
R p R p R p
BioMBaseline vs. LBMBaseline** 0.022 0.9270 0.595 0.0057* 0.536 0.0149*
BioMBR47 vs. leg LBMLoss 0.529 0.0166* 0.102 0.6684 0.453 0.0447*
BioMR3 vs. leg LBMGain -0.580 0.0073* -0.269 0.2509 -0.171 0.4705
Notes
*) represent signiﬁcant difference
**) BioM (Biomarker), Lean Body mass (LBM). Loss is the absolute LBM change during immobilization, i.e. higher negative equals bigger loss; Gain is
total LBM regain during remobilization.
doi:10.1371/journal.pone.0144525.t002
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the biomarker reflect the total level of collagen III steady-state synthesis and thus, by extension,
the amount of LBM.
The finding from the Miller study fits well with the temporal Pro-C3 pattern we observed,
as the Pro-C3 is a biomarker of collagen III synthesis [36]. The further increase in Pro-C3 we
observed during remobilization, also matches well with findings from both animal and human
studies. These have shown increases in collagen protein synthesis and content [36, 37].
While it can appear counterintuitive that counter-directional stimuli produce the same bio-
marker response, we can only speculate that both the detrained and more trained phenotypes
are associated with specific ECMmechanical and compositional profiles that each requires spe-
cific remodeling, thus explaining the changes observed.
Collagen VI is ubiquitously expressed basement membrane protein expressed as heterotri-
mers of alpha1, alpha2 and either alpha3, alpha5 or alpha6 chains (the alpha4 is absent in
humans). However, it appears to be particularly important or at least partially indispensable in
skeletal muscle as genetic defects in α1(VI), α2(VI) or α3(VI) chains result in dystrophic phe-
notypes. In these dystrophic phenotypes creatine kinase is chronically elevated, indicating loss
of sarcolemma integrity [20]. This matches well with the supposed function in which Collagen
VI surrounding cells, help anchor them into the surrounding extra-cellular matrix.
When it comes to discussing the changes in Collagen type VI biomarkers it becomes more
difficult as these are very poorly described in relation to changes in physical activity. There is
essentially no information about collagen type VI expression at mRNA or protein levels in
homogenates or histochemistry in healthy human muscle. Our interest in peptides derived
from Collagen type VI were derived from previous studies, where we found that a biomarker
derived from the α1(VI) chain correlated well with LBM in healthy adults [38] and the fact that
Collagen type VI appears indispensable in skeletal muscle, as mutations in these chains cause
Ullrich and Bethlem Myopathies. The temporal pattern of Pro-C6 during the course of immo-
bilization and subsequent remobilization is similar to Pro-C3.
In muscle it has been shown that the abundance of Collagen type III relative to total collagen
is higher in endomysium, the connective tissue sheath surrounding individual muscle fibers.
Considering that Collagen type VI is a basement membrane protein, their shared pattern could
indicate that protein turnover of the proteins making up the muscle fiber niche are regulated in
a parallel manner.
The correlation analysis revealed that higher levels of Pro-C6 were associated with smaller
loss of muscle during immobilization and higher levels were also associated with a smaller
degree of muscle (re)gain during remobilization. While it may appear counterintuitive, this
may be confounded by the ones that lost the most LBM also regained the most. Collagen type
VI is involved in proper satellite cell function [39] and autophagic function [40], so while there
is plenty of possibly causal and/or mechanistic relationships explaining the temporal pattern
we see, at the present there is inadequate knowledge available for us to suggest which ones
might be at play.
Collagen type III and type VI have different structure and functions in muscle. Collagen
type III is a fibrillar collagen, usually co-distributes with collagen type I. While Collagen type
VI forms a unique microfibrillar network and acts as a linker between the cell skeleton and
ECM. Therefore, their remodeling rate in immobilization and remobilization could be differ-
ent, which could be observed in the specific biomarker responses. C6M is unchanged during
muscle atrophy, and only spikes in the early phase of remobilization, shows some similarity of
creatine kinase [41]. While Pro-C3 shows an initial drop in the early phase of immobilization,
then Pro-C3 and Pro-C6 increase during the atrophy and spike in remobilization.
It is worth noting that none of the biomarkers display significantly different patterns
between the two treatments in the study. This can most likely be attributed to the fact that the
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changes in lean mass with the study were not as large as those reported for total immobiliza-
tion, e.g. from casting. There are significant differences of muscle volume change in some
lower limb (fromMRI) between two groups [27]. We can also observe a loss of 8% LBM (from
DXA) in the lower body in the CTRL group and 4% in the RVE group, however, there is no
change or even a small increase in upper body LBM [30]. As these biomarkers are presumably
produced during connective tissue turnover and released to the circulation, this differential
muscle response translates into a mixed signal in serum, thereby explaining a limited sensitivity
to the different interventions.
Although there is no significant difference between two treatments, Pro-C3, Pro-C6 and
C6M appear to have greater increase in control group, and Pro-C3 and C6M last longer to
return to baseline. This finding might reflect greater muscle loss in control group compared
with RVE group in some of the major postural muscles [27] and potentially more muscle dam-
age [41], which leads to the needs for more muscle re-building.
With increased age or systemic pathologies, fibrogenicity in all tissues increases and eventu-
ally some degree of fibrosis also manifests in muscle. The increase in propeptide biomarkers
observed here, could be understood in that context, i.e. that muscle fibrosis in the elderly or the
seriously ill, is not driven by age or pathology per se, but by repeated cycles of immobilization.
This would parallel the proposed mechanism for age-related muscle loss, which has also been
suggested to be driven by discrete catabolic events, rather than a sustained catabolic or anti-
anabolic drive [42].
While this is obviously hypothetical, immobilization in animal models have also been
shown to lead to intramuscular fibrosis [43, 44].
As these peptide biomarkers are released to the circulation and expressed in many different
tissues it is difficult to prove the exact origin of them. In this paper we are in part just reporting
the temporal patterns and in part comparing them with changes in LBM, in the context of a
bed rest immobilization and remobilization study.
We cannot exclude the possibility that the biomarkers correlations we report are driven by
other effects, e.g. changes in hepatic circulating peptide clearance. Also, we must appreciate the
fact that several processes can contribute to production of biomarker peptides. For example,
even though we report here (and have done so before) that in healthy adults, Pro-C3 correlates
with LBM [14, 38], it has also been shown that other processes increases the amount of collagen
III propeptide in the circulation, like liver fibrosis or anabolic drug administration [12, 14, 45].
Therefore the inferences made about the biomarkers should only be generalized to other popu-
lations with consideration of this.
There is very little scientific literature about the changes in collagen expression and metabo-
lism with unloading and reloading and most of the literature that does exist focuses on colla-
gens I and III using histochemistry, mRNA expression or analysis of hydroxyproline content.
While these findings may help interpreting our collagen III results, there is practically no scien-
tific literature about collagen type VI and collagen type VI peptides, making contextualizing
our findings there very limited.
Conclusion
Immobilization is associated with pronounced modulation of Pro-C3 and Pro-C6, but not
C6M. The upregulation of both Pro-C3 and–C6 likely reflects remodeling of the extracellular
matrix in muscle in response to unloading and reloading. Pro-C6 was related to the anabolic
and catabolic responses to unloading and reloading. Furthermore, we can report that Pro-C3 is
correlated with LBM in young healthy adults, extending previous findings from our group.
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